• 1. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 2. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 3. Achieving molecular stability of racemic 4-O-benzyl-myo-inositol-1,3,5-orthoformate through crystal formation?
  Richa Sardessai,Shobhana Krishnaswamy,Mysore S. Shashidhar CrystEngComm, 2012,14, 8010-8016
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. Alt-proteins: A promising future

Introduction to 2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester (CAS No. 107048-59-9)

2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester, identified by the Chemical Abstracts Service Number (CAS No.) 107048-59-9, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and synthetic biology. This compound serves as a versatile intermediate in the synthesis of various biologically active molecules, particularly in the development of novel therapeutic agents. Its unique structural features, including a bromomethyl group and an alpha-(methoxymethylene) side chain, make it a valuable building block for constructing complex scaffolds that mimic natural products or exhibit novel pharmacological properties.

The bromomethyl substituent at the C-2 position of the benzene ring introduces reactivity that allows for further functionalization through nucleophilic substitution reactions. This feature is particularly useful in constructing heterocyclic compounds or incorporating other functional groups that may enhance the bioactivity of the final product. Additionally, the presence of an alpha-(methoxymethylene) group provides a site for Michael addition reactions or other electrophilic additions, enabling the creation of more intricate molecular architectures. These characteristics make 2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester a valuable reagent in medicinal chemistry and synthetic organic chemistry.

In recent years, there has been growing interest in the development of small-molecule inhibitors targeting specific biological pathways. The compound 107048-59-9 has been explored as a precursor in the synthesis of molecules that interact with enzymes or receptors involved in diseases such as cancer, inflammation, and neurodegenerative disorders. For instance, researchers have utilized this intermediate to develop analogs of known drugs that exhibit improved selectivity or reduced toxicity. The ability to modify both the aromatic core and the side chains allows for fine-tuning of physicochemical properties, such as solubility and metabolic stability, which are critical factors in drug design.

The alpha-(methoxymethylene) moiety is particularly interesting because it can be converted into more stable functional groups under mild conditions, such as hydrolysis to form an aldehyde or ketone. This flexibility makes it easier to integrate into larger molecules without compromising structural integrity. Furthermore, the benzeneacetic acid methylester part of the molecule contributes to its solubility in polar solvents, facilitating its use in solution-phase synthesis. These attributes have made 2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester a preferred choice for researchers aiming to develop novel therapeutics.

Recent advancements in computational chemistry have also enhanced the utility of CAS No. 107048-59-9 by enabling virtual screening and molecular docking studies to identify potential drug candidates more efficiently. By leveraging these computational tools, scientists can predict how modifications to this intermediate will affect its binding affinity to biological targets. This approach has accelerated the discovery process and reduced experimental costs associated with traditional trial-and-error methods. The integration of machine learning algorithms further refines these predictions by analyzing large datasets of known drug interactions.

The pharmaceutical industry has been particularly interested in developing kinase inhibitors, which are essential for treating cancers and inflammatory diseases. The structural motif present in 107048-59-9 closely resembles key pharmacophores found in approved kinase inhibitors. Researchers have synthesized derivatives of this compound that exhibit potent inhibition against specific kinases while maintaining good selectivity over related enzymes. This selectivity is crucial for minimizing side effects and improving patient outcomes. The bromomethyl group allows for further derivatization into more complex structures that can be tailored to enhance binding interactions with target proteins.

Another area where 2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester has shown promise is in the development of antiviral agents. Viruses often rely on host cell machinery for replication, making them susceptible to inhibitors targeting essential viral enzymes or processes. By modifying this intermediate, chemists have been able to create molecules that disrupt viral replication cycles without significant toxicity to host cells. These efforts have been particularly relevant in light of emerging viral threats and the ongoing challenge of antiviral resistance.

The synthesis of CAS No. 107048-59-9 itself is an intriguing process that highlights modern synthetic methodologies. Traditional approaches might involve multi-step sequences with harsh reagents and low yields; however, recent innovations have enabled more efficient routes using catalytic systems or flow chemistry techniques. These advancements not only improve scalability but also reduce waste generation, aligning with green chemistry principles. The ability to produce this compound reliably and cost-effectively has opened new avenues for drug discovery programs worldwide.

The role of this compound extends beyond pharmaceutical applications; it also finds utility in materials science and agrochemical research. For example, researchers have explored its use as a precursor for polymers with unique properties or as a building block for crop protection agents targeting specific pests or pathogens. The versatility of its structure allows chemists to tailor its reactivity toward diverse applications without compromising its core functionality.

In conclusion,2-(Bromomethyl)-alpha-(methoxymethylene)benzeneacetic acid methylester (CAS No. 107048-59-9) represents a cornerstone intermediate in modern synthetic chemistry with far-reaching implications across multiple disciplines including medicine,materials science,and agriculture.Alongside continuous improvementsin synthetic methodologiesand computational tools,the potentialofthis compoundtoyieldnoveltherapeuticsandfunctionalmaterialsremainshighlypromisingforfutureresearchanddevelopmentinitiatives.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)